Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Erbitux Patent Holder Yeda Responds to ImClone Suit

This article was originally published in The Pink Sheet Daily

Executive Summary

Company demands treble damages and non-exclusive licensing deal.

You may also be interested in...



ImClone Finds Itself Facing Another Erbitux Patent Suit

Abbott alleges cell line used to manufacture cetuximab violates one of its patents.

ImClone Finds Itself Facing Another Erbitux Patent Suit

Abbott alleges cell line used to manufacture cetuximab violates one of its patents.

ImClone Reports Promising Erbitux First-Line Colorectal Cancer Results

Company will present data from the Phase III CRYSTAL study at ASCO in June.

Related Content

Topics

UsernamePublicRestriction

Register

OM016808

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel